2020
459-P: Liver-Targeted Mitochondrial Uncoupling by CRMP Improves Whole-Body Insulin Sensitivity and Attenuates Atherosclerosis in A LDLR-/- Mouse Model of Metabolic Syndrome
GOEDEKE L, ROTLLAN N, TOUSSAINT K, NASIRI A, ZHANG X, LEE J, ZHANG X, FERNÁNDEZ-HERNANDO C, SHULMAN G. 459-P: Liver-Targeted Mitochondrial Uncoupling by CRMP Improves Whole-Body Insulin Sensitivity and Attenuates Atherosclerosis in A LDLR-/- Mouse Model of Metabolic Syndrome. Diabetes 2020, 69 DOI: 10.2337/db20-459-p.Peer-Reviewed Original ResearchWhole-body insulin sensitivitySpouse/partnerInsulin sensitivityCardiovascular diseaseMetabolic syndromeAortic root plaque areaHigh fat-cholesterol dietLdlr-/- mouse modelTreatment of CVDEctopic lipid contentLDLR-/- micePeripheral insulin sensitivityNecrotic core areaType 2 diabetesAnti-atherogenic roleFibrous cap areaAdvisory PanelCRMP treatmentAttenuates AtherosclerosisCardiometabolic disordersFatty liverCholesterol dietInsulin resistanceNondiabetic individualsHepatic triglycerides
2019
Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study
Shah VN, DuBose SN, Li Z, Beck RW, Peters AL, Weinstock RS, Kruger D, Tansey M, Sparling D, Woerner S, Vendrame F, Bergenstal R, Tamborlane WV, Watson SE, Sherr J. Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study. The Journal Of Clinical Endocrinology & Metabolism 2019, 104: 4356-4364. PMID: 31127824, PMCID: PMC7296129, DOI: 10.1210/jc.2018-02763.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringMedian timeAge groupsProspective studyNondiabetic individualsGlucose levelsAverage glucoseNonobese body mass indexT1D Exchange Clinic NetworkContinuous glucose monitoring (CGM) profilesInsulin-requiring patientsMulticenter prospective studyBody mass indexDifferent age groupsNondiabetic childrenNondiabetic populationGlycemic profileMass indexNondiabetic participantsGlycemic variabilityMean glucoseClinic networkCGM metricsGlycemic metricsGlucose monitoring
2018
Hypoglycemia unawareness in type 1 diabetes suppresses brain responses to hypoglycemia
Hwang JJ, Parikh L, Lacadie C, Seo D, Lam W, Hamza M, Schmidt C, Dai F, Sejling AS, Belfort-DeAguiar R, Constable RT, Sinha R, Sherwin R. Hypoglycemia unawareness in type 1 diabetes suppresses brain responses to hypoglycemia. Journal Of Clinical Investigation 2018, 128: 1485-1495. PMID: 29381484, PMCID: PMC5873861, DOI: 10.1172/jci97696.Peer-Reviewed Original ResearchConceptsMild hypoglycemiaHypoglycemia awarenessType 1 diabetes mellitus patientsPrefrontal cortexHormonal counterregulatory responsesDiabetes mellitus patientsImpaired hypoglycemia awarenessAltered activation patternsAngular gyrusType 1 diabetesBlood glucose levelsHypoglycemia-induced changesBrain responsesBrain activityHypoglycemia symptom scoresAlters brain activityClinical Translational Science AwardsHyperinsulinemic euglycemicHypoglycemia unawarenessCounterregulatory responsesHypoglycemic clampMellitus patientsMRI brainSymptom scoresNondiabetic individuals
2012
Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual β-Cell Function
Sherr J, Tamborlane WV, Xing D, Tsalikian E, Mauras N, Buckingham B, White NH, Arbelaez AM, Beck RW, Kollman C, Ruedy K. Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual β-Cell Function. Diabetes Care 2012, 35: 817-820. PMID: 22323414, PMCID: PMC3308298, DOI: 10.2337/dc11-2190.Peer-Reviewed Original ResearchConceptsResidual β-cell functionΒ-cell functionSensor glucose levelsLower glucose variabilityType 1 diabetesGlucose levelsContinuous glucose monitoringT1D participantsGlucose variabilityMean sensor glucose levelPeak C-peptide levelsMixed meal tolerance testTarget A1C levelsC-peptide levelsLong-term T1DShort-term groupNondiabetic groupT1D groupA1c levelsT1D patientsLess hyperglycemiaNondiabetic individualsTolerance testInsulin treatmentHypoglycemia
2011
Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease
Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, Still CD, Gerhard GS, Han X, Dziura J, Petersen KF, Samuel VT, Shulman GI. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proceedings Of The National Academy Of Sciences Of The United States Of America 2011, 108: 16381-16385. PMID: 21930939, PMCID: PMC3182681, DOI: 10.1073/pnas.1113359108.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseFatty liver diseaseHepatic DAG contentInsulin resistanceHepatic insulin resistanceLiver diseaseHepatic steatosisCellular mechanismsHomeostatic model assessmentInsulin resistance indexMarkers of inflammationType 2 diabetesER stress markersLipid dropletsHepatic diacylglycerol contentEndoplasmic reticulum stressActivation of PKCεLiver biopsyNondiabetic individualsHepatocellular lipidsInsulin sensitivityCytoplasmic lipid dropletsDAG contentResistance indexAnimal models
2002
Insulin resistance and risk for stroke
Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RI. Insulin resistance and risk for stroke. Neurology 2002, 59: 809-815. PMID: 12349850, DOI: 10.1212/wnl.59.6.809.Peer-Reviewed Original ResearchConceptsInsulin resistanceRisk factorsProspective observational cohort studyType 2 diabetes mellitusInsulin-mediated glucose uptakeObservational cohort studyPrevalent risk factorsImportant risk factorType 2 diabetesCase-control studyPertinent English-language publicationsEnglish-language publicationsCardinal defectsPhysical deconditioningStroke preventionCohort studyMost patientsDiabetes mellitusPathophysiologic defectsNondiabetic individualsVascular diseasePeripheral tissuesElderly personsStrokeDefective glycogen synthesis
1995
Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy
Nishino T, Horii Y, Shiiki H, Yamamoto H, Makita Z, Bucala R, Dohi K. Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy. Human Pathology 1995, 26: 308-313. PMID: 7890283, DOI: 10.1016/0046-8177(95)90063-2.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsGlycosylation end productsSevere diffuse lesionsAnti-AGE antibodyComplications of diabetesInner elastic layerRenal complicationsDiabetic nephropathyAGE antibodyDiffuse lesionsNondiabetic individualsVascular lesionsPathogenic roleAGE accumulationHyaline depositsImmunohistochemical stainingPositive stainingImmunohistochemical detectionAdvanced glycosylationVascular intimaNormal agingSpecific antibodiesTissue distributionEnd productsAntibodies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply